Gilead shares up 1.2% to $10.43 after new reports reveal it has found a vaccine that can prevent hepatitis C in humans
Gileadex has reported its fourth consecutive quarter of positive results from a clinical trial involving a vaccine to treat the rare but deadly liver disease cirrhosis.The company’s shares closed up 1 percent to $12.43 on Friday.The stock has gained more than 30
